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Abstract: Apoptosis, also known as programmed cell death, is a fundamental homeostatic 
mechanism essential for normal embryonic development and the maintenance of healthy adult 
tissues. The processes that affect cell membrane dynamics during the tightly regulated apoptotic 
program have attracted considerable interest over the years. Distinct biochemical and structural 
alterations to plasma membrane composition and topography contribute to the efficient removal 
of cellular corpses. In this review, we will discuss these membrane alterations and their impor-
tance in maintaining cell and tissue homeostasis.
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Introduction
The term “apoptosis” was first used in 1972 by Kerr et al1 to describe a distinct form 
of programmed cell death that contributes to the elimination of excess, unwanted, 
or damaged cells during embryonic development and normal cell turnover in 
healthy adult tissues. The distinct morphological manifestations of a cell undergo-
ing apoptosis include cell shrinkage, membrane blebbing, nuclear and cytoplasmic 
condensation, and ultimately cell fragmentation into membrane bound apoptotic 
bodies.2
Although this programmed cell death mechanism was described earlier, it was in 
the 1980s and 1990s that most of the molecular components governing this highly 
efficient process came to light. Genetic studies on the nematode Caenorhabditis elegans 
were critically important for the elucidation of the apoptotic pathway, revealing the 
ced3, ced4, and ced9 genes as being centrally involved in developmental cell death.3 
It was soon discovered that proteases known as cysteine-dependent aspartate specific 
proteases or caspases were key drivers of the apoptotic program.4–7 Caspases involved 
in apoptosis may be divided into initiator or effector caspases. Intracellular and extra-
cellular apoptotic stimuli activate the initiator caspases 2, 8, 9, and 10, which in turn 
signal via a caspase activation cascade to propagate the death stimulus by activating 
the downstream effector caspases 3, 6, and 7. Activated effector caspases orchestrate 
the destruction of diverse cellular structures by selectively cleaving target proteins to 
elicit the morphological and biochemical features associated with apoptosis (Figure 1). 
Subsequent studies involving targeted genetic disruptions in mice revealed differential 
requirements for specific caspases in mammalian development, some of them display-
ing heart and brain development abnormalities, or even resulting in embryonic and 
perinatal lethality.8
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Apoptosis in development and 
maintenance of tissue homeostasis
A central function of apoptosis in vertebrate development is 
digit formation, since impaired apoptosis leads to ineffective 
removal of cells between developing digits resulting in reten-
tion of interdigital webbing.9 Similarly, the immune system 
uses apoptosis to eliminate developing lymphocytes lacking 
functional antigen receptors.10,11 The role of apoptosis in ner-
vous system development has also been widely recognized, 
where superfluous neurons and neurons that fail to establish 
functional synaptic connections are eliminated.12 Apoptosis 
during embryonic development also helps give tissues and 
organs their form and structure. For example, during gas-
trulation, the conversion of solid embryonic ectoderm into 
hollow closed tubes of columnar epithelial cells is made pos-
sible by apoptosis of inner ectodermal cells.13,14 In addition, 
mechanical force generated by apoptotic cells has recently 
been shown to be vital for inducing tension in developing 
Drosophila melanogaster tissues to induce epithelial folding, 
thus establishing proper topography.15
In addition to its roles in development, apoptosis is also 
important for the maintenance of tissue homeostasis through 
adult life. Cell turnover in adult tissues is highly variable 
across tissue types, and heavily relies on the apoptotic 
machinery to remove damaged and superfluous cells. In 
adults, cell death also plays a key role in tissue remodeling, 
such as mammary gland involution16 and follicular atresia of 
the postovulatory follicle.17 Along with the tightly controlled 
apoptotic program, highly efficient phagocytic mechanisms 
ensure prompt removal of apoptotic debris, thereby reducing 
the potential for apoptotic cells to become necrotic (second-
ary necrosis), resulting in inflammation.18 In contrast to the 
immunologically silent apoptotic process, necrosis may stimu-
late inflammatory responses that could be harmful to tissue 
health. Despite the large number of cells dying by apoptosis 
in adult tissues, it is difficult to detect apoptotic cells even in 
tissues with high cell turnover such as the thymus.19 Defects 
in clearance mechanisms have been linked to inflammation 
and autoimmunity,20 reflecting the importance and efficiency 
of apoptotic cell clearance under normal circumstances.
Cytochrome C
     releaseApoptosome
  formation
Pro-caspase 9 Active caspase 9
Pro-caspase 3/6/7 Active caspase 3/6/7
Pro-caspase 8Active caspase 8
Nuclear
fragmentation 
Membrane
alterations
Organelle
reduction
Extrinsic pathway
Dea
th
ligan
ds
Initiator
caspases 
Effector
caspases 
Cleavage
of death
substrates 
Cytoskeletal
disruption
Intrinsic pathway
Stress, hypoxia,
radiation, etc
Death
 recep
tors
Figure 1 Caspase cascade.
Notes: engagement of extrinsic or intrinsic pathways activates initiator pro-caspases. Active initiator caspases then activate effector pro-caspases. effector caspases cleave 
numerous death substrates to mediate the biochemical apoptotic program.
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Membrane dynamics and  
changes in membrane  
properties during apoptosis
The process of apoptosis includes important changes in 
apoptotic cell membranes that aid in efficient recognition and 
removal. For the purpose of this review, membrane altera-
tions are broadly divided into biochemical and structural.
Biochemical alterations
A common feature of plasma membranes in eukaryotic 
cells is the asymmetric distribution of lipids between the 
inner and outer leaflets, with phosphatidylcholine and 
sphingomyelin predominantly present on the outer leaflet, 
whereas phosphatidylserine (PS), phosphatidylinositol, and 
phosphatidylethanolamine are confined to the cytoplasmic 
face of membranes (Figure 2).21 The maintenance of lipid 
asymmetry under homeostatic conditions is under the control 
of transporters called flippases and floppases.22 A third type 
of enzyme known as scramblases contributes to the loss of 
lipid asymmetry and increased PS extracellular exposure 
when activated.23 Loss of membrane asymmetry and PS 
externalization on the outer leaflet of the plasma membrane 
are common features of apoptotic cells, independent of the 
form of apoptotic stimulus.24,25 However, PS exposure is not 
restricted to apoptotic cells alone, but may also be seen on 
activated platelets.26,27 The events responsible for PS exter-
nalization have been widely debated over the years. Recently, 
Transmembrane Protein 16F, which has a Ca2+-dependent 
phospholipid scramblase activity, was identified as a mediator 
of PS externalization in activated platelets.28,29 In the case of 
apoptotic cells, another scramblase called XK-related protein 
8 that gets activated by caspase cleavage was identified as a 
Ca2+-independent mediator of PS externalization.30 Recent 
work by Segawa et al identified adenosine triphosphate 
type 11C (ATP11C) and cell division cycle protein 50A 
(CDC50A) as being involved in apoptotic PS exposure.31 
ATP11C, a flippase responsible for redirecting PS from the 
outer to the inner leaflet, is inactivated by caspase-mediated 
cleavage.31 CDC50A is required for localization of ATP11C 
to the plasma membrane, and knockout of CDC50A results 
in constitutive PS exposure.31 These data strongly indicate 
that during apoptosis, caspase-mediated activation of Xkr8 
and caspase-mediated inactivation of ATP11C work in a 
coordinated fashion to permit PS exposure (Figure 2).
Early studies confirmed that PS externalization was not 
just an indicator of loss of membrane asymmetry during 
apoptosis, but actually has an important active function to 
play in the clearance of apoptotic cells by acting as a rec-
ognition signal for phagocytic cells.24,32 When receptors on 
phagocytes engage with PS, a signaling cascade is initiated 
within both professional and non-professional phagocytes 
that lead to cytoskeletal rearrangements to facilitate apoptotic 
cell internalization.33,34 A repertoire of PS receptors on mac-
rophages and monocytes has been identified over the years, 
including Stabilin-2, Tim-4, and Bai1.35–37 PS-dependent 
recognition of apoptotic cells may also occur via bridging 
molecules such as milk fat globulin-EGF-factor 8 (MFG-E8) 
and growth arrest-specific gene 6, which tether externalized 
PS on apoptotic cells to the phagocytic receptors.38,39 MFG-E8 
is secreted by activated macrophages to promote tethering of 
PS on apoptotic cells to integrins on phagocytes.38 Growth 
arrest-specific gene 6, which is a ligand for receptor tyrosine 
kinases Mer, also binds to PS to bridge apoptotic cells to 
phagocytes for clearance.39 Although PS externalization 
has been considered to be an important “eat me” signal, it is 
worth noting that since PS trans-bilayer asymmetry is also 
seen in some viable, non-apoptotic cells such as activated 
platelets, which suggested that apoptotic cell engulfment 
requires exceeding a sensitivity threshold for PS exposure.27,40 
However, this theory was challenged when studies showed 
that the levels of PS exposure on viable or apoptotic cells 
were not critical for engulfment by macrophages, suggesting 
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Figure 2 Phosphatidylserine exposure during apoptosis.
Notes: In a healthy cell, PS is restricted to the inner leaflet of the plasma membrane. 
During apoptosis, effector caspases cleave and activate scramblase Xkr8, as well as 
cleave and inactivate flippase ATP11C, resulting in externalization of PS.
Abbreviations: ATP11C, adenosine triphosphate type 11C; PC, phosphatidyl-
choline; Pe, phosphatidylethanolamine; Pi, phosphatidylinositol; PS, phosphatidyl-
serine; SM, sphingomyelin; Xkr8, XK-related protein 8.
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that additional molecules may be required to co-operate with 
PS to aid efficient phagocytosis.41 Interestingly, oxidized PS 
in conjunction with non-oxidized PS was also found to be 
required for efficient apoptotic cell engulfment.42 Over the 
years, a number of molecular determinants and bridging 
ligands have been identified on apoptotic cells including 
C1q, a member of the complement pathway,43 and mannose-
binding lectin, a collectin protein.44
Structural alterations
Apart from these biochemical changes that occur in apop-
totic cells, several dramatic morphological alterations are 
also key events when cells die by apoptosis, as described 
by Kerr et al in their seminal report.1 Broadly termed as the 
execution phase of apoptosis, these structural modifications 
include cell shrinkage, chromatin condensation, nuclear 
fragmentation, and formation of dynamic plasma membrane 
protrusions called blebs, which eventually detach, culminat-
ing in fragmentation into apoptotic bodies.1 These membrane 
protrusions and apoptotic bodies serve as concentration sites 
for phagocytic markers allowing efficient detection and 
engulfment by patrolling phagocytes and/or neighboring 
cells.2,44–46 Packaging of intracellular contents into membrane 
bound apoptotic bodies is believed to be crucial in avoiding 
an unwanted inflammatory response by preventing the release 
of potential self-antigens into the surrounding milieu. Nuclear 
fragments that are not sequestered within apoptotic bodies 
are a source of antigens in autoimmune diseases such as sys-
temic lupus erythematosus (SLE).47,48 Until the early 1990s, 
comprehensive characterization of the execution phase of 
apoptosis remained elusive because of the asynchronous 
nature of apoptotic cell death.49,50
Caspases play major roles both in the commitment phase 
and in the execution phase of apoptosis through their cleav-
age of numerous protein substrates. Adherent cells retract 
from neighboring cells and from extracellular substrates via 
caspase cleavage of β-catenin, a critical regulator of adherens 
junctions,51 and focal adhesion proteins such as tensin.52 
Forces generated by the actin–myosin cytoskeleton induced 
by the phosphorylation of myosin light chains (MLCs) by 
caspase-cleaved Rho-associated coiled coil kinase (ROCK1) 
drive cell contraction and dynamic membrane blebbing dur-
ing apoptosis.53–55 Two phases of plasma membrane blebbing 
were reported in apoptotic cells, with the first phase occurring 
concomitant with cell detachment.56 Several non-adherent 
cell lines fail to display this first phase of blebbing, suggest-
ing a role for the initial phase in maintaining detachment 
from substrate and/or neighboring cells.56 The second phase, 
observed in both adherent and non-adherent cells, results in 
the formation of blebs that contain chromatin and other cel-
lular contents.56 Caspase-mediated cleavage and weakening 
of nuclear structural lamin proteins, as well as contractile 
force generated by the actin–myosin cytoskeleton, result in 
nuclear fragmentation and redistribution of chromatin to the 
blebs and apoptotic bodies.57–60
Cytoskeletal dynamics during 
membrane blebbing
Blebs are blister-like protrusions that occur when cell mem-
branes delaminate from cortical cytoskeletal structures, which 
may appear and disappear on a timescale of minutes. Although 
most often considered in the context of cell death, blebbing 
is also linked to other processes, including locomotion and 
cytokinesis.61,62 Due to their transient nature, little was known 
about blebbing until the discovery of the human melanoma cell 
line M2, deficient in actin–binding protein of 280 kDa (ABP-
280; filamin A), that exhibits prolonged periods of extensive 
plasma membrane blebbing.63,64 Over the years, the physical 
process of blebbing has been carefully investigated using 
various theoretical predictions and biophysical experiments. 
Broadly, the lifecycle of blebs can be subdivided into three 
steps: nucleation, expansion, and retraction (Figure 3).
Nucleation
Nucleation occurs when the cell membrane delaminates from 
the cortical cytoskeleton, an event that reflects a change in the 
balance between cytoplasmic hydrostatic pressure pushing 
outward and the opposing forces of membrane attachment to 
cytoskeletal proteins. Bleb protrusion may be initiated when 
intracellular pressure produced by contraction of cortical 
actin–myosin structures leads to localized compression of the 
cytoplasm. Consistent with a role for actin–myosin contraction, 
inhibition of myosin II activity resulted in abrogation of bleb 
protrusion.53,61,65 Conversely, laser ablation of the actin–myosin 
cortex led to bleb formation in L929 fibroblasts, indicating that 
bleb size and growth are restricted by cortical tension.66 Altera-
tion of ezrin expression in A375 melanoma cells by knockdown 
or overexpression to change the strength of plasma membrane 
coupling to the submembrane cortex resulted in corresponding 
increased or decreased blebbing, respectively.67 This supports 
the conclusion that bleb protrusion results from changes in the 
strength of membrane–cortex coupling.
expansion
Once blebs have been nucleated, they are further expanded 
by pressure generated by actomyosin contraction and the 
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flow of cytosol into the newly formed bleb. Several possible 
mechanisms of bleb expansion to increase surface area has 
been postulated68 including membrane tear from the actin 
cortex69 and unfolding of membrane folds.70 Bleb expansion 
eventually ceases due to transient decreases in local pressure, 
as well as reassembly and/or contraction of the actin–myosin 
cortex,71 at which point retraction may begin.
Retraction
Retraction has been reported to occur approximately 30 sec-
onds after bleb initiation and takes approximately 90 seconds 
for full bleb retraction.71,72 It was reported that initially, 
expanding blebs in filamin-deficient M2 melanoma cells 
are devoid of cortical actin–myosin; however, there is a 
sequential recruitment of the membrane-cortex linker protein 
ezrin, actin, actin-bundling proteins such as α-actinin, and 
contractile proteins including MLC II during cortex reas-
sembly.71 Concomitant with the regrowth of cortical actin 
under bleb membranes, the actin–myosin cortex at the base 
of the bleb disappears, which may serve to supply material 
for reassembly within blebs. These observations have recently 
been challenged using refined image analysis of blebbing 
induced by vaccinia infection of HeLa cells.72 In contrast 
to previous reports, ezrin was detected within blebs prior to 
the onset of retraction while filamentous actin continued to 
accumulate after the onset of retraction. In addition, inhibition 
of Arp2/3 activity, which contributes to nucleating cortical 
actin, reduced bleb retraction speeds, decreased the rate of 
myosin II regulatory light chain recruitment, and increased 
filamentous actin stability, which indicate that filamentous 
actin flux combined with actin–myosin contraction both 
contribute to bleb retraction.
Although the trigger of bleb retraction is still unclear, 
it has been shown that myosin-driven contraction plays a 
role in powering retraction.71 What remains unresolved is 
whether material from the retracted bleb integrates back 
into the cell cortex. It has been observed that occasionally 
secondary blebs appear on existing blebs, possibly because 
of increased pressure within the bleb during retraction that 
might cause membrane to delaminate from the newly formed 
cortex.73 In addition, new blebs may occur at the site of a 
retracted bleb,72 possibly due to instability of the recently 
perturbed actin cortex and/or relatively weak attachments 
between membrane and cortical structures.
Inducers of membrane blebbing
Although blebbing may be observed during several cellular 
processes including cytokinesis, migration, and spread-
ing, arguably its most totemic manifestation is during the 
execution phase of apoptosis.24 Despite being one of the 
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hallmark features of apoptosis, little was known about the 
mechanistic drivers underlying this phenomenon until the 
1990s. Various studies showed that reorganization of cytoskel-
etal structures drives the formation of membrane blebs and 
apoptotic bodies.53 Disruption of filamentous actin inhibited 
the formation of apoptotic bodies without affecting DNA 
fragmentation, indicating a requirement for polymerized 
actin during the later stages of apoptosis.74 One early study 
implicating myosin contraction in bleb formation showed 
that microinjecting an active form of MLC kinase resulted 
in active surface blebbing during mitosis.75 Subsequently, it 
was shown that blebbing cells had increased levels of myosin 
II regulatory light chain phosphorylation and that inhibition 
of MLC kinase activity decreased blebbing.53 Actin–myosin 
contractile force generation results from the phosphorylation 
of the regulatory MLCs, which promotes myosin binding 
to filamentous actin, coupling of actin–myosin filaments to 
linker proteins at the plasma membrane, and ATP-dependent 
actin–myosin filament contraction.76,77 Inhibition of myosin 
contractility with the myosin II ATPase blocker blebbistatin 
reduced apoptotic blebbing.78
Two homologues of the serine/threonine kinase ROCKs 
(ROCK1 and ROCK2) have been identified as downstream 
effectors of Rho.79 ROCKs have dual roles in the regulation 
of MLC phosphorylation in that they directly phosphorylate 
MLC and decrease dephosphorylation indirectly by phospho-
rylating and inhibiting the MLC-binding MYPT1 subunit of 
the phosphatase complex.80–82 Apoptotic membrane blebbing 
was found to be dependent on ROCK activity and independent 
of the function of its upstream regulator, RhoA.54,55 During 
apoptosis, activated caspases cleave ROCK1 after a aspartate-
glutamate-threonine-aspartate (amino acids 1,110–1,113) 
sequence, thus removing the autoinhibitory C terminal region 
and generating a truncated kinase fragment with increased 
intrinsic activity. The ROCK kinase fragment generated can 
phosphorylate downstream targets including MLC, leading 
to actin–myosin contractile force generation, cell contractil-
ity, and consequent membrane blebbing and apoptotic body 
formation. The significance of ROCK1 for apoptotic blebbing 
has been shown in other cell types, including cardiac myo-
cytes, lymphoma cells, and non-small-cell lung carcinoma 
cells.83–85 Of notable importance was the relocalization of 
fragmented DNA into blebs and apoptotic bodies upon 
caspase-activated ROCK1 cleavage.54 In addition to these 
morphological responses, ROCK1 activity was also required 
for nuclear envelope tearing and disintegration.60 During 
the early stages of rapid membrane blebbing and apoptotic 
body release, there may be leakage of damage-associated 
molecular pattern proteins, such as nucleosomal histones, 
highlighting a possible role for blebbing cells and apoptotic 
bodies to alert the immune cells for efficient phagocytic uptake 
prior to secondary necrosis.86 In the specialized case of cell 
death induced by natural killer cells, Granzyme B cleaves 
ROCK2 at a homologous position to the caspase-cleavage 
site on ROCK1, leading to constitutive ROCK2 activation 
that is sufficient to promote caspase-independent membrane 
blebbing.55 However, given that Granzyme B also activates 
caspases leading to ROCK1 activation, there are no obvious 
situations where ROCK2 would be activated without con-
comitant ROCK1 activation in apoptotic cells.
Pathological consequences  
of dysfunction in apoptotic 
membrane dynamics
The final phase during the active apoptotic program is the 
clearance of cell corpses and the associated debris, a process 
termed efferocytosis, derived from the Latin word “effero” 
meaning “to bury”.87 The fact that it is difficult to detect apop-
totic cells in situ, even in tissues with high cellular turnover, 
indicates that clearance mechanisms are highly efficient and 
rapid. Several elegant studies have shown that apoptotic cells 
release “find me” signals including lysophosphatidylcholine, 
sphingosine-1-phosphate, fractalkine, and the nucleotides 
ATP and UTP to “advertise” their presence to local and 
distant phagocytes, as reviewed previously.88,89 Once alerted, 
phagocytes must be capable of distinguishing live cells from 
the dead, and this is facilitated by different biochemical and 
structural alterations that occur on the plasma membrane of 
apoptotic cells as discussed above. Since the apoptotic pro-
gram is immunologically silent during development and in 
adult steady-state tissues, largely due to the efficient removal 
of apoptotic cells, it is not surprising that disturbances in the 
rapid recognition and removal of the apoptotic debris may 
lead to pathological consequences.
Autoimmunity
Apoptotic cells that linger in tissues due to inefficient 
clearance mechanisms may undergo secondary necrosis, 
allowing intracellular antigens to be recognized as non-self, 
thus leading to autoantibody production and consequent 
autoimmunity development.90–92 One of the most widely 
studied pathological consequences of failed clearance of 
apoptotic debris is SLE, which is a chronic autoimmune 
disorder affecting multiple organs.93,94 Evidence gleaned from 
several genetic mouse models bearing defective PS-mediated 
recognition of apoptotic cells suggests a strong link between 
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inefficient apoptotic debris clearance and development of 
autoimmunity.92,95–98 Given the fact that there are multiple PS 
recognition mechanisms, it is intriguing that these mecha-
nisms are not redundant in suppressing the autoimmune 
phenotype in these mouse models. In accordance with the 
mouse data, accumulation of apoptotic cells was observed in 
SLE patients, which was attributed to impaired efferocytosis 
rather than an aberrant apoptotic program.99–101 Defects in 
structural alterations of apoptotic cells can be attributed to 
the lack of a proper display of membrane modifications. C1q 
has been shown to bind to apoptotic blebs of keratinocytes45 
and vascular endothelial cells,46 suggesting a possible role 
for apoptotic blebs as focal points for “eat me” signals, to 
enable efficient efferocytosis.2 C1q-deficient mice exhibited 
the autoimmune phenotype of glomerulonephritis, as well 
as an increased number of uncleared apoptotic bodies in the 
glomeruli, implying defective clearance.90
Nevertheless, animal model studies have revealed that 
not all defects in apoptotic clearance mechanisms lead to 
autoimmunity. One example is the non-development of 
autoimmunity in animals lacking mannose-binding lectin, a 
collectin that shares functional similarities with C1q, binds 
to apoptotic cells, and plays a major role in clearance of 
apoptotic cells in vivo.102 It is possible that the uncleared 
apoptotic debris has an immunosuppressive effect that helps 
prevent autoimmunity in these animals, which would require 
further investigation to validate.
Cancer
In addition to evasion of cell death as a hallmark feature 
of cancer cells, escaping programmed cell removal has 
also surfaced as a determinant in cancer development.103,104 
Whether apoptotic membrane defects or aberrant clearance 
mechanisms have beneficial or detrimental effects in the 
context of tumor progression has been ardently debated over 
many years. Expression levels of “eat me” and “don’t eat me” 
are altered in tumor cells as revealed by several animal 
model studies and human genetic studies. Pro-phagocytic 
markers such as annexin 1 have been found to be reduced 
at the mRNA and protein levels in several human cancers 
including prostate cancer, esophageal cancer, and head and 
neck cancer.105,106 In addition, “don’t eat me” signals such 
as CD47 and CD200 were upregulated in lung, breast, and 
prostate and bladder cancer.107 Although these studies imply 
that tumors adopt evasion of apoptotic clearance as a cancer 
promoting strategy, several studies reported upregulation of 
different apoptotic recognition molecules such as PS108,109 
and calreticulin104 in tumor cells, raising questions regarding 
the role of efficient apoptotic cell clearance in the context 
of tumorigenesis.
Chronic inflammation is a key driver of tumorigenesis.110–112 
Efficient clearance mechanisms are accompanied by the 
production of anti-inflammatory mediators, resulting in 
an immunosuppressive environment. Given the high levels 
of cell death that can occur within a tumor microenviron-
ment, clearance defects could trigger antitumor immune 
responses, as demonstrated by the inhibition of PS recog-
nition of lymphoma cells that impaired immunosuppres-
sive clearance and heightened tumor immunogenicity.113 
Conversely, inflammation caused by delayed or inefficient 
clearance may favor tumor growth by providing a suitable 
environment, facilitating genomic instability and promoting 
angiogenesis.114 Hence, both possibilities have to be carefully 
deliberated while interpreting the role of dysfunctional clear-
ance mechanisms in tumors.
Conclusion
Alterations in the plasma membrane during apoptosis, both 
structural and biochemical, play crucial roles in discriminat-
ing dying cells from their healthy counterparts. These mor-
phological features ensure efficient recognition and clearance 
of apoptotic debris by phagocytes to maintain homeostatic 
equilibrium. Hence, it is not surprising that defects in these 
alterations may have significant implications in diseases 
including autoimmunity and cancer.
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